Monitoring the operationally tolerant liver allograft recipient

Current Opinion in Organ Transplantation

Volumn 15, Issue 1, 2010, Pages 28-34

  Castellaneta, Antonino ^a,b   Thomson, Angus W ^b   Nayyar, Navdeep ^a   De Vera, Michael ^b   Mazariegos, George V ^a,b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Immune monitoring; Microarray analysis; Tolerance registry; Transplant tolerance

Indexed keywords

ALEMTUZUMAB; ANTIBODY; BIOLOGICAL MARKER; CASPASE RECRUITMENT DOMAIN PROTEIN 15; DONOR ANTIBODY; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; LEUKOCYTE ANTIGEN; LEUKOCYTE ANTIGEN G; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLOGRAFT; BIOPSY; BLOOD SAMPLING; CLINICAL ASSESSMENT; CLINICAL TRIAL; DENDRITIC CELL; DNA POLYMORPHISM; DRUG WITHDRAWAL; EXPERIMENTAL TRANSPLANTATION; GRAFT RECIPIENT; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LABORATORY TEST; LIVER GRAFT; LIVER TRANSPLANTATION; MICROARRAY ANALYSIS; MONITORING; MULTICENTER STUDY; REGISTER; REGULATORY T LYMPHOCYTE; REVIEW;

BIOLOGICAL MARKERS; BIOPSY; DRUG ADMINISTRATION SCHEDULE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MICROARRAY ANALYSIS; PREDICTIVE VALUE OF TESTS; REGISTRIES; T-LYMPHOCYTE SUBSETS; TIME FACTORS; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 75749139037     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e328334269a     Document Type: Review

References (71)

1. Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation: how much of the promise has been realized? Nat Med 2005; 11:605-613.
2. Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 2005; 56:23-46.
3. Sayegh MH, Carpenter CB. Transplantation 50 years later: progress, challenges, and promises. N Engl J Med 2004; 351:2761-2766.
4. Eksteen B, Neuberger JM. Mechanisms of disease: the evolving understanding of liver allograft rejection. Nat Clin Pract Gastroenterol Hepatol 2008; 5:209-219.
5. Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997; 63:243-249.
6. Reyes J, Zeevi A, Ramos H, et al. Frequent achievement of a drug-free state after orthotopic liver transplantation. Transplant Proc 1993; 25:3315-3319.
7. Koshiba T, Li Y, Takemura M, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol 2007; 17:94-97.
8. Mazariegos GV, Sindhi R, Thomson AW, Marcos A. Clinical tolerance following liver transplantation: long term results and future prospects. Transpl Immunol 2007; 17:114-119.
9. Orlando G, Manzia T, Baiocchi L, et al. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months. Transpl Immunol 2008; 20:43-47.
10. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant 2006; 6:1774-1780.
11. Orlando G, Soker S, Wood K. Operational tolerance after liver transplantation. J Hepatol 2009; 50:1247-1257.
12. Demetris AJ, Lunz 3rd JG, Randhawa P, et al. Monitoring of human liver and kidney allograft tolerance: a tissue/histopathology perspective. Transpl Int 2009; 22:120-141.
13. Yoshitomi M, Koshiba T, Haga H, et al. Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation 2009; 87:606-614.
14. Turka LA, Lechler RI. Towards the identification of biomarkers of transplantation tolerance. Nat Rev Immunol 2009; 9:521-526.
15. Newell KA, Larsen CP. Tolerance assays: measuring the unknown. Transplantation 2006; 81:1503-1509.
16. Mazariegos GV, Zahorchak AF, Reyes J, et al. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant 2003; 3:689-696.
17. Mazariegos GV, Zahorchak AF, Reyes J, et al. Dendritic cell subset ratio in tolerant, weaning and nontolerant liver recipients is not affected by extent of immunosuppression. Am J Transplant 2005; 5:314-322.
18. Brouard S, Mansfield E, Braud C, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A 2007; 104:15448-15453.
19. Martinez-Llordella M, Lozano JJ, Puig-Pey I, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008; 118:2845-2857.
20. Tokita D, Mazariegos GV, Zahorchak AF, et al. High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. Transplantation 2008; 85:369-377.
21. Gupta A, Kumar CA, Ningappa M, et al. Elevated myeloid: plasmacytoid dendritic cell ratio associates with late, but not early, liver rejection in children induced with rabbit antihuman thymocyte globulin. Transplantation 2009; 88:589-594.
22. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006; 82:663-668.
23. Pons JA, Revilla-Nuin B, Baroja-Mazo A, et al. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. Transplantation 2008; 86:1370-1378.
24. Li Y, Koshiba T, Yoshizawa A, et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004; 4:2118-2125.
25. Ashokkumar C, Talukdar A, Sun Q, et al. Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation. Am J Transplant 2009; 9:179-191.
26. Mazariegos GV, Reyes J, Webber SA, et al. Cytokine gene polymorphisms in children successfully withdrawn from immunosuppression after liver transplantation. Transplantation 2002; 73:1342-1345.
27. Basturk B, Karakayali F, Emiroglu R, et al. Human leukocyte antigen-G, a new parameter in the follow-up of liver transplantation. Transplant Proc 2006; 38:571-574.
28. Fabrega E, Unzueta MG, Cobo M, et al. Value of soluble CD30 in liver transplantation. Transplant Proc 2007; 39:2295-2296.
29. Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002; 2:151-161.
30. Ito T, Yang M, Wang YH, et al. Plasmacytoid dendritic cells prime IL-10- producing T regulatory cells by inducible costimulator ligand. J Exp Med 2007; 204:105-115.
31. Gilliet M, Liu YJ. Generation of human CD8 T regulatory cells by CD40 ligandactivated plasmacytoid dendritic cells. J Exp Med 2002; 195:695-704.
32. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27:195-201.
33. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027-1034.
34. Guleria I, Khosroshahi A, Ansari MJ, et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med 2005; 202:231-237.
35. Abe M, Wang Z, de Creus A, Thomson AW. Plasmacytoid dendritic cell precursors induce allogeneic T-cell hyporesponsiveness and prolong heart graft survival. Am J Transplant 2005; 5:1808-1819.
36. Louis S, Braudeau C, Giral M, et al. Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006; 81:398-407.
37. Gagne K, Brouard S, Giral M, et al. Highly altered V beta repertoire of T cells infiltrating long-term rejected kidney allografts. J Immunol 2000; 164:1553-1563.
38. Brouard S, Dupont A, Giral M, et al. Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Am J Transplant 2005; 5:330-340.
39. Hunt JS, Petroff MG, McIntire RH, Ober C. HLA-G and immune tolerance in pregnancy. FASEB J 2005; 19:681-693.
40. Rouas-Freiss N, Naji A, Durrbach A, Carosella ED. Tolerogenic functions of human leukocyte antigen G: from pregnancy to organ and cell transplantation. Transplantation 2007; 84:S21-25.
41. Le Rond S, Azema C, Krawice-Radanne I, et al. Evidence to support the role of HLA-G5 in allograft acceptance through induction of immunosuppressive/ regulatory T cells. J Immunol 2006; 176:3266-3276.
42. Naji A, Le Rond S, Durrbach A, et al. CD3+CD4low and CD3+CD8low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood 2007; 110:3936-3948.
43. LeMaoult J, Caumartin J, Daouya M, et al. Immune regulation by pretenders: cell-to-cell transfers of HLA-G make effector T cells act as regulatory cells. Blood 2007; 109:2040-2048.
44. LeMaoult J, Zafaranloo K, Le Danff C, Carosella ED. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 2005; 19:662-664.
45. Qiu J, Terasaki PI, Miller J, et al. Soluble HLA-G expression and renal graft acceptance. Am J Transplant 2006; 6:2152-2156.
46. Lila N, Amrein C, Guillemain R, et al. Human leukocyte antigen-G expression after heart transplantation is associated with a reduced incidence of rejection. Circulation 2002; 105:1949-1954.
47. Mao Q, Terasaki PI, Cai J, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7:864-871.
48. Terasaki PI, Cai J. Humoral theory of transplantation: further evidence. Curr Opin Immunol 2005; 17:541-545.
49. Lee PC, Terasaki PI, Takemoto SK, et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2002; 74:1192-1194.
50. Itescu S, Tung TC, Burke EM, et al. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for highgrade cellular rejection in recipients of heart transplantation. Circulation 1998; 98:786-793.
51. Girnita AL, Duquesnoy R, Yousem SA, et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant 2005; 5:131-138.
52. Shapiro R, Zeevi A, Basu A, et al. Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. Transplantation 2008; 85:1125-1132.
53. de Capei U, Dametto ME, Fasano ME, et al. Cytokines and chronic rejection: a study in kidney transplant long-term survivors. Transplantation 2004; 77: 548-552.
54. Poole KL, Gibbs PJ, Evans PR, et al. Influence of patient and donor cytokine genotypes on renal allograft rejection: evidence from a single centre study. Transpl Immunol 2001; 8:259-265.
55. Hackstein H, Kluter H, Fricke L, et al. The IL-4 receptor alpha-chain variant Q576R is strongly associated with decreased kidney allograft survival. Tissue Antigens 1999; 54:471-477.
56. Hahn AB, Kasten-Jolly JC, Constantino DM, et al. TNF-alpha, IL-6, IFNgamma, and IL-10 gene expression polymorphisms and the IL-4 receptor alpha-chain variant Q576R: effects on renal allograft outcome. Transplantation 2001; 72:660-665.
57. Hutchings A, Guay-Woodford L, Thomas JM, et al. Association of cytokine single nucleotide polymorphisms with B7 costimulatory molecules in kidney allograft recipients. Pediatr Transplant 2002; 6:69-77.
58. Awad MR, Webber S, Boyle G, et al. The effect of cytokine gene polymorphisms on pediatric heart allograft outcome. J Heart Lung Transplant 2001; 20:625-630.
59. Asderakis A, Sankaran D, Dyer P, et al. Association of polymorphisms in the human interferon-gamma and interleukin-10 gene with acute and chronic kidney transplant outcome: the cytokine effect on transplantation. Transplantation 2001; 71:674-677.
60. Dmitrienko S, Hoar DI, Balshaw R, Keown PA. Immune response gene polymorphisms in renal transplant recipients. Transplantation 2005; 80: 1773-1782.
61. Fernandes H, Koneru B, Fernandes N, et al. Investigation of promoter polymorphisms in the tumor necrosis factor-alpha and interleukin-10 genes in liver transplant patients. Transplantation 2002; 73:1886-1891.
62. Bathgate AJ, Pravica V, Perrey C, et al. The effect of polymorphisms in tumor necrosis factor-alpha, interleukin-10, and transforming growth factor-beta1 genes in acute hepatic allograft rejection. Transplantation 2000; 69:1514-1517.
63. Pelletier R, Pravica V, Perrey C, et al. Evidence for a genetic predisposition towards acute rejection after kidney and simultaneous kidney-pancreas transplantation. Transplantation 2000; 70:674-680.
64. Alakulppi NS, Kyllonen LE, Jantti VT, et al. Cytokine gene polymorphisms and risks of acute rejection and delayed graft function after kidney transplantation. Transplantation 2004; 78:1422-1428.
65. Hoffmann S, Park J, Jacobson LM, et al. Donor genomics influence graft events: the effect of donor polymorphisms on acute rejection and chronic allograft nephropathy. Kidney Int 2004; 66:1686-1693.
66. Wramner LG, Norrby J, Hahn-Zoric M, et al. Impaired kidney graft survival is associated with the TNF-alpha genotype. Transplantation 2004; 78:117-121.
67. Marder B, Schroppel B, Murphy B. Genetic variability and transplantation. Curr Opin Urol 2003; 13:81-89.
68. Holweg CT, Weimar W, Uitterlinden AG, Baan CC. Clinical impact of cytokine gene polymorphisms in heart and lung transplantation. J Heart Lung Transplant 2004; 23:1017-1026.
69. Fishbein T, Novitskiy G, Mishra L, et al. NOD2-expressing bone marrowderived cells appear to regulate epithelial innate immunity of the transplanted human small intestine. Gut 2008; 57:323-330.
70. Fekete A, Viklicky O, Hubacek JA, et al. Association between heat shock protein 70s and toll-like receptor polymorphisms with long-term renal allograft survival. Transpl Int 2006; 19:190-196.
71. Eid AJ, Brown RA, Paya CV, Razonable RR. Association between toll-like receptor polymorphisms and the outcome of liver transplantation for chronic hepatitis C virus. Transplantation 2007; 84:511-516.